GO
Loading...

Johnson & Johnson

More

  • Midday Glance: Medical Devices companies Wednesday, 3 Sep 2014 | 1:34 PM ET

    Allergan fell $1.44 or. 9 percent, to $165.01. Baxter International Inc. rose$. 43 or. 6 percent, to $74.20. Boston Scientific Corp. fell$. 04 or. 3 percent, to $12.56.

  • Early Glance: Pharmaceuticals companies Wednesday, 3 Sep 2014 | 10:28 AM ET

    Baxter International Inc. rose$. 48 or. 7 percent, to $74.25. Bristol-Myers Squibb Co. rose$. 12 or. 2 percent, to $50.70. Hospira fell$. 07 or. 1 percent, to $54.15.

  • Early Glance: Medical Devices companies Wednesday, 3 Sep 2014 | 10:28 AM ET

    Allergan fell$. 48 or. 3 percent, to $165.97. Baxter International Inc. rose$. 48 or. 7 percent, to $74.25. Boston Scientific Corp. rose$. 05 or. 4 percent, to $12.64.

  • *Novartis's LCZ696 and PCSK9 drugs could treat millions. Hopes have spiked for a heart failure drug from Novartis and an innovative class of injectable anti-cholesterol agents known as PCSK9 inhibitors after the release of data at the ESC's annual meeting indicated that they can save more lives than standard therapies.

  • Early movers: BIG, GOOG, S, AVGO, AZN, AAPL & more Friday, 29 Aug 2014 | 7:34 AM ET
    Traders work on the floor of the New York Stock Exchange (NYSE).

    Some of the names on the move ahead of the open.

  • NEW YORK, Aug 29- U.S. stock index futures were modestly higher on Friday, suggesting the market's recent upswing was intact and pointing to a fourth straight week of gains for major indexes.

  • Aug 28- Johnson& Johnson plans to seek a buyer for its medical device maker business, Cordis Corp, The Wall Street Journal reported citing people familiar with the matter. Earlier this year, J&J sold another of its units, Ortho-Clinical Diagnostics Inc to private-equity firm Carlyle Group for $4.15 billion.

  • Midday movers: AIG, Amgen, Lear & more Thursday, 28 Aug 2014 | 2:07 PM ET
    Traders work on the floor of the New York Stock Exchange in New York.

    Some of Thursday's midday movers:

  • Johnson & Johnson recalls some jaw implants Thursday, 28 Aug 2014 | 9:44 AM ET
    DePuy Synthes Craniomaxillofacial Distraction System.

    The FDA said the recall was classified as the most serious Class 1 type, where there is a probability of serious health problems or death.

  • Aug 28- Johnson& Johnson is recalling some lots of its implant used to correct defects of the jaw, following more than a dozen cases of injury.

  • FDA says Johnson & Johnson recalls some jaw implants Thursday, 28 Aug 2014 | 8:17 AM ET

    Aug 28- Johnson& Johnson is recalling some lots of its implant used to correct defects of the jaw following more than a dozen cases of injury. The device, which is used to lengthen and stabilize the lower jawbone and the side of the lower jaw, is being recalled by JNJ unit DePuy Synthes as it may reverse after surgery.

  • WASHINGTON, Aug 27- International Business Machines Corp on Wednesday launched a computer system that can quickly identify patterns in massive amounts of data, an ability that IBM said should hasten breakthroughs in science and medical research. IBM will make the service available through the cloud.

  • There's still hunger for 'blockbuster' biotech deals Monday, 25 Aug 2014 | 10:58 AM ET
    Severin Schwan, chief executive officer Roche Holding.

    Roche's deal for InterMune is one of the few this year that returns to the traditional model of big pharma buying smaller biotech.

  • Near 2,000, S&P knocks out 28th record close of 2014 Thursday, 21 Aug 2014 | 4:07 PM ET
    Traders work on the floor of the New York Stock Exchange in New York.

    Stocks rose Thursday as investors anticipate a dovish tone from Federal Reserve Chair Janet Yellen on Friday.

  • Vertex to end sales of hepatitis C drug Incivek Wednesday, 13 Aug 2014 | 2:42 PM ET

    Aug 13- Vertex Pharmaceuticals Inc is stopping U.S. sales and distribution of its Incivek hepatitis C treatment, whose use has been largely supplanted by the new Sovaldi drug from Gilead Sciences Inc.. Incivek was approved in 2011 and quickly rose to annual sales of more than $1 billion.

  • Aug 13- BioCryst Pharmaceuticals Inc said the U.S. government exercised options to test the company's antiviral drug in humans and non-primates as a treatment for hemorrhagic fever viruses such as Ebola.

  • *Liberia to treat infected doctors with trial drug ZMapp. LONDON/ GENEVA, Aug 12- People infected in the West African Ebola outbreak can be offered untested drugs, the World Health Organisation said on Tuesday, but the scarcity of supplies has raised questions about who gets priority access to treatment.

  • *Liberia to treat infected doctors with trial drug ZMapp. LONDON/ GENEVA, Aug 12- People infected in the West African Ebola outbreak can be offered untested drugs, the World Health Organisation said on Tuesday, but the scarcity of supplies raises questions about who gets priority access to treatment.

  • Priceline earnings lesson for Apple investors Monday, 11 Aug 2014 | 6:44 PM ET

    Did you catch Priceline earnings? Jim Cramer thinks there’s an important lesson for Apple investors.

  • The Ebola epidemic in West Africa has killed nearly 1,000 people and prompted the World Health Organization to declare an international health emergency. GSK is co-developing a vaccine with the U.S. National Institute of Allergy and Infectious Diseases, which has shown promising results in primates.